"Leukemia is a devastating disease," says Ashok Krishnamurthi, "for the patient and for the family." When this illness touched a family member, Krishnamurthi and his brother, R.K. Anand, did extensive research on treatment facilities, learning that the Division of Hematology/Oncology at UCSF was one of the best.
Although great strides and successes have been made in leukemia treatment, especially in children, there is still much to be done. Four out of five adults diagnosed with leukemia eventually die of the disease.
The Krishnamurthi family is working to help change that outcome. After bringing their relative from India to be treated at UCSF, the family made two pledges totaling $2 million to establish a leukemia clinical research fund and the Krishnamurthi Endowed Chair in Hematologic Malignancies at UCSF.
"We want to do what we can to make life easier for the patient," explains Krishnamurthi, "and also promote advanced research that will make a difference for future patients."
The chair will support the work of Charles Linker, MD
, co-leader of the Hematopoietic Malignancies Program at the UCSF Comprehensive Cancer Center, and his colleagues. Faculty in this multidisciplinary program are involved in pace-setting translational research -- believing that clinical aspects of leukemia and lymphoma can inform basic research and, conversely, that these laboratory investigations will ultimately lead to improved patient care.
(Note that in November 2007 the UCSF Comprehensive Cancer Center was renamed the UCSF Helen Diller Family Comprehensive Cancer Center.)
Read more at Philanthropy Insider, UCSF Foundation